Skip to content

Comparative study of the lipids effects of telmisartan and valsartan in patients with STEMI

Comparative study of the lipids effects of telmisartan and valsartan in patients with STEMI

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251213068301N1
Enrollment
248
Registered
2025-12-25
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction (MI). ST elevation (STEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Telmisartan. Intervention 2: Intervention group: Valsartan.

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients with STEMI Abdicación clases 1 for ACE OR ARB

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Lipid profile including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. Timepoint: 3 m after starting the medication. Method of measurement: Blood sampling and serum testing with a standard blood biochemistry analyzer.;Serum creatinine level and glomerular filtration rate (GFR) indicating kidney function. Timepoint: Before starting the medication and 3 m after starting the medication. Method of measurement: Blood sample and serum analysis with standard device.

Secondary

MeasureTime frame
Systolic and diastolic blood pressure of patients. Timepoint: Before starting the medication, 4 weeks after starting the medication. Method of measurement: Standard mercury sphygmomanometer.;Body mass index (BMI) of patients. Timepoint: Before starting the medication, 4 weeks after starting the medication. Method of measurement: Measuring height and weight with a standard scale and tape measure.;Fasting blood glucose level. Timepoint: Before starting the medication, 4 weeks after starting the medication. Method of measurement: Blood sample and serum test with standard blood biochemistry analyzer.;Adverse drug reactions. Timepoint: During the treatment period. Method of measurement: Questionnaire and clinical interview.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohamad taghi pour

Qazvin University of Medical Sciences

mohamad.taghipoor70@gmail.com+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026